{"preliminary_commentary":{"by_channel":{"x_thread":58,"podcast":15,"youtube":8},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03141671\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["abiraterone","apalutamide"]],"indication":"prostate cancer with rising PSA after radical prostatectomy","name":"FORMULA-509","nct_id":"NCT03141671","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=formula-509-nct03141671. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"* GnRH agonist injection monthly or every 3 months for 6 months\n* Bicalutamide by mouth once/day for 6 months\n* Salvage radiation (starting 4-10 weeks after initiation of ADT)","label":"GnRH + Bicalutamide","type":"EXPERIMENTAL"},{"description":"* GnRH agonist injection monthly or every 3 months for 6 months\n* Abiraterone acetate by mouth once/day for 6 months\n* Prednisone by mouth once/day for 6 months\n* Apalutamide by mouth once/day for 6 months\n* Salvage radiation (starting 4-10 weeks after initiation of ADT)","label":"GnRH+Abiraterone+Apalutamide+Prednisone","type":"EXPERIMENTAL"}],"collaborators":["Janssen Pharmaceutica"],"completion_date":{"date":"2025-12-31","type":"ESTIMATED"},"conditions":["Prostate Cancer"],"enrollment":{"count":345,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"GnRH","otherNames":["LHRHA"],"type":"DRUG"},{"name":"Bicalutamide","otherNames":["Casodex"],"type":"DRUG"},{"name":"Salvage radiation","otherNames":[],"type":"RADIATION"},{"name":"Abiraterone","otherNames":["Zytiga"],"type":"DRUG"},{"name":"Prednisone","otherNames":["Deltasone"],"type":"DRUG"},{"name":"Apalutamide","otherNames":["ARN-509"],"type":"DRUG"}],"last_update":"2024-05-14","lead_sponsor":"Dana-Farber Cancer Institute","official_title":"Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)","overall_status":"UNKNOWN","phases":["PHASE2"],"primary_completion_date":{"date":"2025-04-05","type":"ESTIMATED"},"primary_outcomes":[{"measure":"PSA Progression Free Survival","timeFrame":"Up to 5 years"}],"references":[],"start_date":{"date":"2017-11-24","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)","url":"https://clinicaltrials.gov/study/NCT03141671"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/formula-509-nct03141671"}